Related Experiment Video
Updated: Jul 8, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Adjuvant treatment and survival in obese women with endometrial cancer: an international collaborative study
Francesca Martra1, Charles Kunos, Heidi Gibbons
1Department of Gynecologic Oncology, University of Turin, Mauriziano Umberto I Hospital, Turin, Italy.
Objective:
The purpose of this study was to determine the impact of patient weight on the frequency of surgical staging lymphadenectomy and pelvic radiation. Adverse effects, disease relapse, and survival outcomes were investigated.
Study Design:
Records of 766 women who underwent surgery for presumed corpus-confined endometrial cancer were reviewed. Body mass index (BMI) was calculated to categorize women as obese (BMI, > or = 30 kg/m2) or nonobese (BMI, < 30 kg/m2). Radiation-related toxicity was scored retrospectively. Median duration of follow-up period was 38 months. Chi2, logistic regression, correlation, Kaplan-Meier, and Cox multivariate proportional hazards were used for analysis.
Results:
Lymphadenectomy was completed as often in nonobese as obese women (P = .24). Adjuvant pelvic radiation treatment was administered more often in nonobese women (P = .01). Among 681 women with endometrioid histopathologic findings, 4-year cancer-related survival in obese women was 10% higher than all cause deaths, compared with 6% in nonobese women.
Conclusion:
Obesity was not a barrier to lymphadenectomy, but did influence adjuvant pelvic radiation use.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Drug Dosing: Obese Patients
Cancer Survival Analysis
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion